Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,209,247 papers from all fields of science
Search
Sign In
Create Free Account
Taselisib
An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
GDC-0032
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Can PI3K Inhibitors Reduce Endocrine Therapy Resistance in Early Breast Cancer
D. Levitan
2019
Corpus ID: 202825196
The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole…
Expand
2018
2018
Taselisib Modestly Delays Progression in ER+ Breast Cancer
B. Furlow
2018
Corpus ID: 145955428
The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.
2018
2018
Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal…
E. Azambuja
,
C. Saura
,
+24 authors
M. Gnant
2018
Corpus ID: 80625386
2017
2017
Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients…
M. V. Oliveira
,
R. Baird
,
+21 authors
S. Linn
2017
Corpus ID: 78938759
Background: The combination of PI3K-AKT-mTOR pathway inhibitors with endocrine therapy can improve clinical outcomes of hormone…
Expand
2017
2017
Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating…
M. Dickler
,
C. Saura
,
+8 authors
J. Baselga
2017
Corpus ID: 79226487
Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast…
Expand
2017
2017
Abstract 1780: Identifying preclinical predictive biomarkers to taselisib in breast cancer cell lines
H. Savage
,
H. Moore
,
+4 authors
T. Wilson
2017
Corpus ID: 80386073
2016
2016
Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or…
J. Baselga
,
J. Cortes
,
+10 authors
S. Verma
2016
Corpus ID: 77190125
Background:PIK3CA mutations are one of the most frequent genomic alterations in breast cancer (BC), being present in ∼40% of…
Expand
2016
2016
Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive…
Takeshi Kobayashi
,
K. Nakano
,
+16 authors
S. Takahashi
2016
Corpus ID: 76022417
Background: Taselisib (GDC-0032) is an orally bioavailable, potent and selective phosphoinositide 3-kinase (PI3K) inhibitor…
Expand